AnaptysBio Inc. announced results from its global Phase 2 clinical trial evaluating investigational rosnilimab in patients with moderate-to-severe ulcerative colitis. The study found that rosnilimab was safe and well tolerated, with adverse event rates similar to placebo. However, the trial did not meet its primary endpoint of mean change from baseline in modified Mayo Score or key secondary endpoints of clinical response and clinical remission at Week 12. As a result, AnaptysBio will discontinue the ulcerative colitis trial. The company plans to provide an update in the first half of 2026 on the advancement of rosnilimab for rheumatoid arthritis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572393-en) on November 10, 2025, and is solely responsible for the information contained therein.